HAC (Russian)
RSCI (Russian)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Tocolytic therapy with hexoprenaline in pregnant women at risk for premature birth. The impact of ADRB2 gene polymorphism on tocolysis

DOI: https://doi.org/10.29296/25877305-2021-09-08

G. Proklova(1); Associate Professor R. Chilova(1), MD; Associate Professor E. Sokova(1, 2),
Candidate of Medical Sciences; R. Kazakov(2), Candidate of Biological Sciences; E. Zhukova(1), Candidate of
Medical Sciences; K. Akopov(3) (1)I.M. Sechenov First Moscow State Medical University (Sechenov University),
Ministry of Health of Russia (2)Research Center for Examination of Medical Products, Ministry of Health of
Russia, Moscow (3)S.S. Yudin City Clinical Hospital, Branch, Female Counseling Center Three, Moscow

Premature birth (PB) is the main cause of mortality and morbidity in newborns without congenital malformations or chromosomal aberrations. Objective: to evaluate the significance of the ADRB2 gene polymorphism in predicting the efficiency and safety of tocolytic pharmacotherapy with β2-adrenostimulants in pregnant women with PB. Subjects and methods. The investigation involved 120 pregnant women, including 60 women at risk for PB who received tocolytic therapy with hexoprenaline as indicated; and 60 ones at no risk for PB. The Gly16Arg and Gln27Glu polymorphisms in the ADRB2 gene were determined in all the study participants. The findings were compared with the indicators of the efficiency and safety of hexoprenaline therapy. Results. The 16Arg allele of the ADRB2 gene was 1.54 times more common in parturients with a normal pregnancy than in patients at risk for PB (the result was insignificant at the accepted significance level, but close to it: χ2=3.8218; p=0.05059). Hexoprenaline therapy prolonged pregnancy to a period of >37 weeks in 65% of the patients with PB. The efficacy of hexoprenaline was lower in the carriers of the genotypes indicating the high or low expression of β2-adrenoreceptors.

obstetrics and gynecology
premature birth
single nucleotide polymorphisms

  1. Serov V.N., Tjutjunnik V.L. Taktika lechenija ugrozhajuschih prezhdevremennyh rodov. RMZh. 2008; 16 (19): 1252–5 [Serov V.N., Tyutyunnik V.L. Tactics for the treatment of threatened premature birth. RMJ. 2008; 16 (19): 1252–5 (in Russ.)].
  2. Surina M.N., Chvanova E.A. Techenie beremennosti i ee ishody u patsientok s defitsitom massy tela. Fundamental'naja i klinicheskaja meditsina. 2018; 3 (3): 65–70 [Surina M.N., Chvanova E.A. Pregnancy course and outcomes in women with low body mass index. Fundamental and Clinical Medicine. 2018; 3 (3): 65–70 (in Russ.)]. DOI: 10.23946/2500-0764-2018-3-3-65-70
  3. Haas D.M., Quinney S.K., McCormick .CL. et al. A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic. J Matern Fetal Neonatal Med. 2012; 25 (4): 419–23. DOI: 10.3109/14767058.2011.583700
  4. Miller R.S., Smiley R.M., Daniel D. et al. Beta-2 adrenoceptor genotype and progress in term and late preterm active labor. Am J Obstet Gynecol. 2011; 205 (2): 137.e1–137.e7. DOI: 10.1016/j.ajog.2011.03.045